Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
January 19 2021 - 5:05PM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced
that it will be presenting preliminary results from an ongoing
SARS-CoV-2 mutation surveillance program for its neutralizing
antibodies currently in clinical and pre-clinical development for
treatment of patients with COVID-19 disease.
Dr. Robert Allen, Senior Vice President, Antiviral and Oncolytic
Immunotherapy Development at Sorrento and Chief Scientific Officer
of SmartPharm Therapeutics, will be presenting data from the
SARS-CoV-2 Spike protein variant screening program at PepTalk 2021
today and on Thursday of this week.
- January 19, 2021 at 1:25 PM
PSTA Novel Low-Immunogenic DNA Plasmid Encoded with a
Therapeutic Antibody for Long-Lasting Expression in vivo against
COVID-19
- January 21, 2021 at 2:45 PM
PSTAn Antibody’s Story: A Journey from Phage Library to an
IND of STI 1499
Disclosed data will provide evidence of maintained binding
potency by STI-2020 in in vitro assays including the Spike amino
acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage
initially identified in the United Kingdom which has since been
detected in ten U.S states. This is highly clinically relevant as
it might signify that the STI-2020 antibody currently in clinical
trials is not anticipated to behave differently against the new
virus variant predicted by the CDC to potentially become the
dominant virus variant infecting people in the US as early as March
2021.
Sorrento will also provide early in vitro results of diminished
STI-2020 binding potency in assays including Spike proteins derived
from viruses of the B.1.351 lineage first identified in South
Africa, but yet undetected in the United States.
Additional neutralizing antibodies were identified that bind
strongly to the B.1.1.7 and B.1.351 spike proteins and are under
further analyses for neutralization activities both in vitro and in
vivo. Upon further validation, the most promising antibody clones
will be selected as potential candidates to be added as components
of our COVI-SHIELD antibody cocktail as dictated by the continued
emergence of mutations in clinical isolates. Sorrento believes it
has in place highly potent antibodies against the most recent UK
and South Africa viral variants for inclusion in
COVI-SHIELD-2021.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to treat
cancers. Sorrento's multimodal, multipronged approach to fighting
cancer is made possible by its extensive immuno-oncology platforms,
including key assets such as fully human antibodies (“G-MAB™
library”), clinical stage immuno-cellular therapies (“CAR-T”,
“DAR-T”), antibody-drug conjugates (“ADC”), and clinical stage
oncolytic virus (“Seprehvir®”). Sorrento is also developing
potential antiviral therapies and vaccines against coronaviruses,
including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™,
COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including
COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients
is also demonstrated by our effort to advance a first-in-class
(TRPV1 agonist) non-opioid pain management small molecule,
resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium
phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation
of a widely used corticosteroid for epidural injections to treat
lumbosacral radicular pain, or sciatica, and to commercialize
ZTlido® (lidocaine topical system) 1.8% for the treatment of
post-herpetic neuralgia. RTX has completed a phase IB trial for
intractable pain associated with cancer and a phase 1B trial in
osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for
the treatment of lumbosacral radicular pain, or sciatica. ZTlido®
was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc. under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the binding potency of
STI-2020; the preclinical testing of STI-2020 with respect to viral
variants of the SARS-CoV-2 virus, including the B.1.1.7 and B.1.351
variants; the potential clinical relevance and/or significance of
such preclinical testing; the identification of neutralizing
antibodies that potentially bind strongly to variants in vitro
and/or in vivo; and the potential potency of the COVI-SHIELD-2021
antibody cocktail against current or future variants resulting from
mutations. Risks and uncertainties that could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements, include, but are not limited to:
risks related to Sorrento's and its subsidiaries', affiliates’ and
partners’ technologies and prospects and collaborations with
partners; clinical development risks for STI-2020 and
COVI-SHIELD-2021, including risks in the progress, timing, cost,
and results of clinical trials and product development programs;
risk of difficulties or delays in obtaining regulatory approvals;
risks that clinical study results may not meet any or all endpoints
of a clinical study and that any data generated from such studies
may not support a regulatory submission or approval; risks that
prior test, study and trial results may not be replicated in future
studies and trials; risks related to seeking regulatory approvals
and conducting clinical trials; the viability and success of
STI-2020 and COVI-SHIELD-2021 in anti-viral therapeutic areas;
risks of manufacturing and supplying drug product; risks related to
leveraging the expertise of its employees, subsidiaries, affiliates
and partners to assist the company in the execution of its
therapeutic and diagnostic product candidate strategies; risks
related to the global impact of COVID-19; and other risks that are
described in Sorrento's most recent periodic reports filed with the
Securities and Exchange Commission, including Sorrento’s Annual
Report on Form 10-K for the year ended December 31, 2019, and
subsequent Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission, including the risk factors set forth in
those filings. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this release and we undertake no obligation to update any
forward-looking statement in this press release except as required
by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (SVP Corporate
Development)Telephone: 1.858.203.4120Email:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.G-MAB™, DAR-T™, COVI-GUARD™, COVI-AMG™,
COVI-SHIELD™, Gene-MAb™, COVI-DROPS™, COVI-MSC™, COVI-TRACK™,
COVI-TRACE™ and COVI-STIX™ are trademarks of Sorrento Therapeutics,
Inc.SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.ZTlido®
is a registered trademark owned by Scilex Pharmaceuticals Inc.All
other trademarks are the property of their respective owners.
© 2021 Sorrento Therapeutics, Inc. All Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024